Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients = 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy

摘要

Regorafenib was shown to improve survival of patients with metastatic colorectal cancer resistant or unfit for all available therapies. Data on the efficacy and safety of regorafenib in elderly patients are scarce. In this small analysis, regorafenib administered with a modified schedule (2 weeks-on/1 week-off) to patients who were aged = 75 and non-frail with late-stage metastatic colorectal cancer appears to be tolerable and effective.